Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its chief executive officer said in an interview.

Humira (adalimumab) is a biologic medication used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. For years, it has been one of ...

Scientists at The Wistar Institute have developed an HIV vaccine candidate that achieves something never before observed in ...

Perenco UK has injected the first tonnes of CO 2 into a depleted reservoir as part of Poseidon, a carbon storage project in the Perenco-operated Leman gas field. This is the first time a CO 2 ...

Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 ...

Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that ...

ABU DHABI, 5th January, 2026 (WAM) -- Yas Clinic – Khalifa City, in collaboration with the Abu Dhabi Stem Cells Centre (ADSCC) and Vertex Pharmaceuticals, and with the support and oversight of the ...

Scientists at The Wistar Institute have developed an HIV vaccine candidate that achieves something never before observed in ...

The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric ...

In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections ...

New Afrezza prescribing information outlines higher starting dose conversions for patients transitioning from mealtime insulin to improve glycemic control.

The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.